Telaprevir for chronic hepatitis C with genotype 1: A meta-analysis

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 461-468

  Dang, Shuang Suo ^a   Wang, Wen Jun ^a   Wang, Xiu Fang ^a   Li, Ya Ping ^a   Li, Mei ^a   Jia, Xiao Li ^a   Wang, Yuan ^a   Liu, Enqi ^a   Zhao, Sihai ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Genotype 1; Hepatitis C; Meta analysis; Telaprevir

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR;

ARTICLE; CLINICAL ASSESSMENT; DRUG EFFECT; GENOTYPE; HEMORRHOID; HEPATITIS C; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860548472     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11312     Document Type: Article

References (60)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362. (Pubitemid 19117877)
2. www.who.int/immunization/topics/hepatitis-c/en/.
3. Alberti A, Benvegnù L: Management of hepatitis C. J Hepatol 2003; 38:S104-S118.
4. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492. (Pubitemid 28543496)
5. Cammà C, Bruno S, Schepis F, et al.: Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patients data. Gut 2002; 51:864-869. (Pubitemid 35408610)
6. Cummings KJ, Lee SM, West ES, et al.: Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285:193-199. (Pubitemid 32048522)
7. Jensen DM, Marcellin P, Freilich B, et al.: Re-treatment of patients with chronic hepatitis who do not respond to peginterferon-2b. Ann Intern Med 2009; 150:528-540.
8. Poynard T, Colombo M, Bruix J, et al.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136:1613-1628.
9. Kolykhalov AA MK, Feinstone SM, Rice CM: Hepatitis C virusencoded enzymatic activities and conserved RNA elements in the 3- nontranslated region are essential for virus replication in vivo. J Virol 2000; 74:2046-2051. (Pubitemid 30434065)
10. Lin C KA, Perni RB: Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16.
11. Higgins J AD: Assessing risk of bias in included studies. In: Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1. Oxford, England: Cochrane Collaboration, 2008.
12. Van den Eynde E, Tiraboschi JM, Tural C, et al.: Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS 2010; 24:975-982.
13. Reesink HW, Fanning GC, Farha KA, et al.: Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients. Gastroenterology 2010; 138:913-921.
14. McHutchison JG, Manns MP, Muir AJ, et al.: Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362:1292-1303.
15. Brok J, Gluud LL, Gluud C: Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev 2010:CD005445.
16. Clinical trial investigates two experimental HCV drugs. AIDS Patient Care STDS 2010; 24:270.
17. Susser S, Welsch C, Wang Y, et al.: Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-1718.
18. Shiffman ML, Morishima C, Dienstag JL, et al.: Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial. Gastroenterology 2009; 137:1986-1994.
19. Reesink HW, Weegink CJ: New hope for a cure for chronic hepatitis C. J Hepatol 2009; 51:835-837.
20. Pan JJ, Firpi RJ: The management of hepatitis C. Minerva Gastroenterol Dietol 2009; 55:23-35.
21. Neukam K, Macias J, Mira JA, Pineda JA: A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin Pharmacother 2009; 10:417-433.
22. McHutchison JG, Manns MP, Muir A, et al.: PROVE3 final results and 1-year durability of SVR with telaprevir-based regimen in hepatitis C genotype 1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Hepatology 2009; 50:334A-335A.
23. McHutchison JG, Everson GT, Gordon SC, et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
24. Marcellin P, Forns X, Goeser T, Ferenci P, et al.: Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon-alfa-2a or -alfa- 2b and ribavirin in treatment - naive patients with genotype 1 hepatitis C: study C208. Hepatology 2009; 50:395A.
25. Manns MM: Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferonalfa-2A/B and ribavirin therapy: SVR results of the PROVE3 study. J Hepatol 2009; 50:S379.
26. Jensen DM, Marcellin P, Freilich B, et al.: Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-alpha 2b A Randomized Trial. Ann intern Med 2009; 150:528-540.
27. Hotho D, de Bruijne J, O'Farrell A, et al.: Accelerated clinical trial design to assess the safety, tolerability and anti-viral activity of PHX1766, a novel HCV NS3/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients. Hepatology 2009; 50:1031A-1032A.
28. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
29. Foster GR, Hezode C, Bronowicki JP, et al.: Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis C patients: interim results of study C209. J Hepatol 2009; 50:S22.
30. Everson GT, Dusheiko GM, Ferenci P, et al.: Telaprevir, peginterferon alfa - 2a and ribavirin improved rates of sustained virologic response (SVR) in "Difficult-to-Cure" patients with chronic hepatitis C (CHC) : a pooled analysis from the PROVEl and PROVE2 trials. Hepatology 2009; 50:1025A.
31. Di Bisceglie AM, Muir AMJ, Adda N, et al.: SVR results of PROVE3, a phase 2B clinical trial assessing safety and efficacy of telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy. Gastroenterology 2009; 136:116A.
32. Benhamou Y, Moussalli J, Ratziu V, et al.: Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon ALFA-2A and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 2009; 50:S6.
33. Baiocchi L, Lenci I, Carbone M, Angelico M: Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!". Hepatology 2009; 50:1676-1677.
34. Zeuzem S, Hezode C, Ferenci P, et al.: Telaprevir in combination with peginterferon-alfa-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology 2008; 48:418A-419A.
35. Stauber RE, Kessler HH: Drugs in development for hepatitis C. Drugs 2008; 68:1347-1359. (Pubitemid 351913433)
36. Muir AJ, Lawitz EJ, McHutchison JG, et al.: Viral responses in African-Americans, Latinos and Caucasians in the US phase 2 study (PROVE1) of telaprevir with peginterferon a-2a and ribavirin in treatment-naive genotype 1-infected subjects with hepatitis C. Hepatology 2008; 48:1131A.
37. McHutchison JG, Shiffman ML, Terrault N, et al.: A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa-2a/b and ribavirin therapy: PROVE3 interim results. Hepatology 2008; 48:269A-270A.
38. McHutchison JG, Everson GT, Gordon SC, et al.: PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. J Hepatol 2008; 48:S4.
39. Liu-Young G, Kozal MJ: Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 2008; 22:449-457.
40. Gelderblom HC, Zeuzem S, Weegink CJ, et al.: Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand J Gastroenterol 2008; 43:1122-1127.
41. Forns X, Marcellin P, Goeser T, et al.: Phase 2 study of telaprevir administered q8h orq12h with peginterferon-alfa-2a or -alfa-2b and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results. Hepatology 2008; 48:1136A-1137A.
42. Forestier N, Sarrazin C, Friedrich-Rust M, Zeuzem S: Status of pat ients with chronic hepatitis C after a pretreatment period of 14 days with Telaprevir (VX-950) und a following antiviral therapy with Peg-interferon-alfa-2a (Peg-IFN-2s) and ribavirin (RBV). Zeitschrift fur Gastroenterologie 2008; 46:145.
43. Dusheiko GM, Hezode C, Pol S, et al.: Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE2 study. J Hepatol 2008; 48:S26.
44. Weegink CJ, Forestier N, Jansen PL, Zeuzem S, Reesink HW: Final results of patients receiving peg-interferon-alfa-2a (Peg-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950), with Peg-IFN. Hepatology 2007; 46:819A.
45. Vermehren J, Sarrazin C: Protease inhibitors in the treatment of chronic hepatitis C: Commentary. Zeitschrift fur Gastroenterologie 2007; 45:1085-1088. (Pubitemid 350083278)
46. Sarrazin C, Kieffer TL, Bartels D, et al.: Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology 2007; 132:1767-1777. (Pubitemid 46677938)
47. Zeuzem S, Hezode C, Ferenci P, et al.: PROVE2: Phase Il sstudy of VX950 (telaprevir) in combination with peginterferon alfa2A with or without ribavirin in subjects with chronic hepatitis C,first interim analysis. Hepatology 2007; 46:268A-269A.
48. Pawlotsky J, Kieffer T, Zhou Y, et al.: Evaluation of viral variants during a phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naive HCV genotype 1-infected patients. Hepatology 2007; 46:862A.
49. McHutchison JG, Everson GT, Gordon S, et al.: Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon alpha-2a and ribavirin in previously untreated subjects with hepatitis C. J Hepatol 2007; 46:5296.
50. Kieffer TL, Sarrazin C, Miller JS, et al.: Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639. (Pubitemid 47436107)
51. Jacobson IM, Everson GT, Gordon SC, et al.: Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. Hepatology 2007; 46:315A-316A.
52. Gelderblom HC, Zeuzem S, Weegink CJ, et al.: Neopterin and ALT as markers of inflammation in chronic hepatitis C patients during administration of the HCV NS3-4a protease inhibitor telaprevir (VX-950) in combination with peginterferon alfa 2a. J Hepatol 2007; 46:S224-S225.
53. Friedrich-Rust M, Forestier N, Sarrazin C, Reesink HW, Herrmann E, Zeuzem S: Ultrasound Evaluation of Perihepatic Lymph Nodes During Antiviral Therapy with the Protease Inhibitor Telaprevir (VX-950) in Patients with Chronic Hepatitis C Infection. Ultrasound Med Biol 2007; 33:1362-1367. (Pubitemid 47302190)
54. Forestier N, Sarrazin C, Friedrich-Rust M, et al.: Status of patients with chronic hepatitis C after a 14-day pre-treatment with Telaprevir (VX-950) followed by an anti-viral therapy with Peg-interferon-alpha-2a (Peg-IFN-2a) and Ribavirin (RBV). Zeitschrift fur Gastroenterologie 2007; 45:841.
55. Forestier N, Reesink HW, Weegink CJ, et al.: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46:640-648. (Pubitemid 47436108)
56. Reesink HW, Zeuzem S, Weegink CJ, et al.: Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX950: A Phase Ib, Placebo-Controlled, Randomized Study. Gastroenterology 2006; 131:997-1002. (Pubitemid 44498690)
57. Reesink HW, Forestier N, Weegink CJ, et al.: Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-apha-2a. J Hepatol 2006; 44:S272.
58. Inchauspe G: HEP DART 2005 - HCV therapeutics. IDrugs 2006; 9:168-170.
59. Forestier N, Weegink CJ, Purdy S, et al.: Current status of subjects receiving peg-interferon-alfa-2A (peg-ifn) and ribavirin (RBV) after a 14-day study of the hepatitis C protease inhibitor telaprevir (VX-950), with peg-ifn. Hepatology 2006; 44:614A-615A.
60. Chu HM, Herrmann E, Reesink HW, et al.: Pharmacokinetics of VX-950, and its effect on hepatitis C viral dynamics. Hepatology 2005; 42:694A-695A.